Ignite Creation Date:
2024-05-06 @ 2:34 PM
Last Modification Date:
2024-10-26 @ 1:33 PM
Study NCT ID:
NCT04355520
Status:
UNKNOWN
Last Update Posted:
2020-04-21
First Post:
2020-04-20
Brief Title:
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase Ib Single-arm Open-label Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2020-02
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a open-label multicenter phase Ib study to evaluate safety and efficacy of TQ-B3525 tablets combined with fulvestrant injection in subjects with HR-positive HER2-negative and PIK3CA mutation advanced breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None